Sutro Biopharma (STRO) Current Deferred Revenue (2017 - 2025)
Historic Current Deferred Revenue for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $9.0 million.
- Sutro Biopharma's Current Deferred Revenue fell 8762.82% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 8762.82%. This contributed to the annual value of $69.8 million for FY2024, which is 23767.06% up from last year.
- Latest data reveals that Sutro Biopharma reported Current Deferred Revenue of $9.0 million as of Q3 2025, which was down 8762.82% from $12.0 million recorded in Q2 2025.
- In the past 5 years, Sutro Biopharma's Current Deferred Revenue registered a high of $74.0 million during Q2 2024, and its lowest value of $5.5 million during Q4 2021.
- Over the past 5 years, Sutro Biopharma's median Current Deferred Revenue value was $16.8 million (recorded in 2022), while the average stood at $25.6 million.
- Per our database at Business Quant, Sutro Biopharma's Current Deferred Revenue surged by 31009.09% in 2024 and then crashed by 8762.82% in 2025.
- Quarter analysis of 5 years shows Sutro Biopharma's Current Deferred Revenue stood at $5.5 million in 2021, then soared by 204.93% to $16.8 million in 2022, then increased by 23.31% to $20.7 million in 2023, then soared by 237.67% to $69.8 million in 2024, then plummeted by 87.14% to $9.0 million in 2025.
- Its Current Deferred Revenue stands at $9.0 million for Q3 2025, versus $12.0 million for Q2 2025 and $69.0 million for Q1 2025.